Dr. Gupta on Unmet Needs in Frontline Treatment of Metastatic Urothelial Cancer.

In Partnership With:

Shilpa Gupta, MD, discusses the unmet needs of patients with cisplatin-ineligible metastatic urothelial carcinoma.

Shilpa Gupta, MD, oncologist, Hematology and Medical Oncology, Cleveland Clinic, discusses the unmet needs of patients with cisplatin-ineligible metastatic urothelial carcinoma (mUC).

A minority of patients with mUC receive second-line therapy, indicating there is still a need to improve patient survival in the first-line setting. Treatment selection in the frontline is determined by the patient's eligibility for the platinum-based therapy.

Less than 10% of patients with mUC are truly platinum-ineligible. The consensus definition for determining complete platinum-ineligibility involves an ECOG performance status of 3 or higher, peripheral neuropathy grade 2 or higher, significant heart failure, and a creatine clearance (CrCL) of less than 30 ml/minute.

Patients who are determined to be platinum-eligible will typically receive cisplatin-based chemotherapy. If they do not progress on chemotherapy, this regimen will be followed by maintenance avelumab (Bavencio). Patients who are cisplatin-ineligible could receive atezolizumab (Tecentriq) or pembrolizumab (Keytruda). However, they are usually directed towards the current preferred standard of gemcitabine in combination with carboplatin, followed by maintenance avelumab.

Related Videos
View All
Related Content